Kendahl L. Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kendahl L. Ott has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. LeBeau
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
29 shared publications - Joshua Michael Lang
Carbone Cancer Center, University of Wisconsin, Madison, USA
27 shared publications - David Kosoff
Department of Medicine University of Wisconsin‐Madison Madison Wisconsin USA
26 shared publications - Gihan S. Gunaratne
Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
26 shared publications - Jayden L. West
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
26 shared publications - Joseph P. Gallant
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
26 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Current Protocols
- Vol. 6 (7) , e70414
High Throughput In vivo Imaging; A Pipeline for Automated Analysis of Longitudinal Preclinical Studies
Fast acquisition times, multi‐animal beds, and improved accessibility of preclinical imaging systems have enabled high‐throughput imaging, significantly accelerating in vivo experimentation. However, image analysis remains largely manual, labor‐intensive, and inefficient, with significant inter‐ and intra‐user variability, adding to the already lengthy timeline of preclinical validation. This article outlines an end‐to‐end pipeline for image acquisition and subject preprocessing, followed by deep learning‐based segmentation and reporting of metrics relevant for validation. This pipeline is applicable to imaging studies investigating biodistribution, dosimetry, disease progression, and treatment effect over time. A longitudinal positron emission tomography–computed tomography (PET‐CT) case study is used to demonstrate the protocol in a practical animal research context. The protocol encompasses image acquisition and reconstruction, fusion, cropping, sorting, metadata addition, deep learning‐based and interactive organ and tumor segmentation, 3‐dimensional visualization, and extraction of quantitative uptake curves. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Image Acquisition and Reconstruction Basic Protocol 2 : Multi‐Subject Cropping and Sorting Basic Protocol 3 : Atlas Alignment and Segmentation Basic Protocol 4 : Quantitation and Reporting
- 8 July 2026
- Published by Wiley in Current Protocols
- Vol. 6 (7) , e70414
Open AccessHigh Throughput In vivo Imaging; A Pipeline for Automated Analysis of Longitudinal Preclinical Studies
Fast acquisition times, multi‐animal beds, and improved accessibility of preclinical imaging systems have enabled high‐throughput imaging, significantly accelerating in vivo experimentation. However, image analysis remains largely manual, labor‐intensive, and inefficient, with significant inter‐ and intra‐user variability, adding to the already lengthy timeline of preclinical validation. This article outlines an end‐to‐end pipeline for image acquisition and subject preprocessing, followed by deep learning‐based segmentation and reporting of metrics relevant for validation. This pipeline is applicable to imaging studies investigating biodistribution, dosimetry, disease progression, and treatment effect over time. A longitudinal positron emission tomography–computed tomography (PET‐CT) case study is used to demonstrate the protocol in a practical animal research context. The protocol encompasses image acquisition and reconstruction, fusion, cropping, sorting, metadata addition, deep learning‐based and interactive organ and tumor segmentation, 3‐dimensional visualization, and extraction of quantitative uptake curves. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Image Acquisition and Reconstruction Basic Protocol 2 : Multi‐Subject Cropping and Sorting Basic Protocol 3 : Atlas Alignment and Segmentation Basic Protocol 4 : Quantitation and Reporting
- Open Access
- 29 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) is synthesized as transmembrane TNF-α (tmTNF-α) where proteolytic processing releases soluble TNF-α (sTNF-α). tmTNF-α can act as either a ligand by activating TNF receptors, or a receptor that transmits reverse (outside-to-inside) signalling after binding to native receptors. All TNF-α therapies bind tmTNF-α and induce reverse signalling which can result in immunosuppression leading to infection. We present crystal structures of two anti-TNF-α Variable New Antigen Receptors (VNARs) in complex with sTNF-α via two distinct epitopes. The VNAR-D1 recognizes an epitope that selectively engages sTNF-α while VNAR-C4 binds an epitope that partially overlaps with other biologic therapies. In activated CD4+ T cells, our VNARs do not induce reverse signalling in contrast to currently available therapies. Our findings suggest that neutralization through a unique mechanism may lead to anti-TNF-α agents with an improved safety profile that will benefit high-risk patients.
- 29 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) is synthesized as transmembrane TNF-α (tmTNF-α) where proteolytic processing releases soluble TNF-α (sTNF-α). tmTNF-α can act as either a ligand by activating TNF receptors, or a receptor that transmits reverse (outside-to-inside) signalling after binding to native receptors. All TNF-α therapies bind tmTNF-α and induce reverse signalling which can result in immunosuppression leading to infection. We present crystal structures of two anti-TNF-α Variable New Antigen Receptors (VNARs) in complex with sTNF-α via two distinct epitopes. The VNAR-D1 recognizes an epitope that selectively engages sTNF-α while VNAR-C4 binds an epitope that partially overlaps with other biologic therapies. In activated CD4+ T cells, our VNARs do not induce reverse signalling in contrast to currently available therapies. Our findings suggest that neutralization through a unique mechanism may lead to anti-TNF-α agents with an improved safety profile that will benefit high-risk patients.
- Open Access
- 13 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1210
The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for the development of therapies to mitigate immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique properties of Variable New Antigen Receptors (VNARs) from shark immunoglobulins. Through the direct immunization of a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and by an in silico approach that did not require any affinity maturation. We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro when attached to an anti-mitotic payload and were able to localize to FAP-positive xenografts in vivo by positron emission tomography. Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
- 13 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1210
Open AccessThe characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for the development of therapies to mitigate immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique properties of Variable New Antigen Receptors (VNARs) from shark immunoglobulins. Through the direct immunization of a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and by an in silico approach that did not require any affinity maturation. We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro when attached to an anti-mitotic payload and were able to localize to FAP-positive xenografts in vivo by positron emission tomography. Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
- Open Access
Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
Open AccessDevelopment of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines